Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation

International Journal of Neuropsychopharmacology

Volumn 12, Issue 5, 2009, Pages 589-597

  O'Malley, Stephanie S ^a   Krishnan Sarin, Suchitra ^a   McKee, Sherry A ^a   Leeman, Robert F ^a   Cooney, Ned L ^a   Meandzija, Boris ^a   Wu, Ran ^a   Makuch, Robert W ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Drinking reduction; Heavy drinking; Measurement sensitivity; Naltrexone; Smoking cessation

Indexed keywords

NALTREXONE; NICOTINE; NICOTINE PATCH; PLACEBO;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; SMOKING; SMOKING CESSATION;

EID: 69749096667     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570800936X     Document Type: Article

References (31)

1. Acheson A, Mahler SV, Chi H, de Wit H (2006). Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology (Berlin) 186, 54-63.
2. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berlin) 173, 32-40.
3. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, et al. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Journal of the American Medical Association 295, 2003-2017.
4. Babor TF, de la Fuente JR, Saunders J, Grant M (1992). AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization.
5. 11)C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biological Psychiatry 55, 255-262.
6. Brady LS (1992). Opiate receptor regulation by opiate agonists and antagonists. In: Hammer RP (Ed.), Neurobiology of Opiates (pp. 125-143). Boca Raton, FL: CRC Press.
7. Doty P, deWit H (1995). Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behavioral Pharmacology 6, 386-394.
8. Doty P, Kirk JM, Cramblett MJ, deWit H (1997). Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment. Drug and Alcohol Dependence 47, 109-116.
9. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. Journal of the American Medical Association 293, 1617-1625.
10. Heatherton TF, Kozlowski LK, Frecker RC, Fagerström KO (1991). The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 86, 1119-1127.
11. Institute of Medicine (1990). Broadening the Base of Treatment for Alcohol Problems. Washington, DC: National Academy Press.
12. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R (2003). Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology 23, 294-304.
13. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS (2007). Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biological Psychiatry 62, 694-697.
14. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ (2000a). Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22, 480-492.
15. McCaul ME, Wand GS, Rohde C, Lee SM (2000b). Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinking. Alcoholism: Clinical and Experimental Research 24, 1385-1391.
16. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001). Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25, 537-547.
17. McKee SA, O'Malley SS, Shi J, Mase T, Krishnan-Sarin S (2008). Transdermal nicotine replacement attenuates alcohol reactivity and reduces alcohol self-administration. Psychopharmacology 196, 189-200.
18. Miller WR, Wilbourne P (2003). Whatever happened to controlled drinking? Alcoholism: Clinical and Experimental Research 27 (Suppl. 5), 111A.
19. Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC (2007). The Asp40 m-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. Journal of Clinical Psychopharmacology 27, 112-115.
20. NIAAA (2005). Helping Patients Who Drink too Much: A Clinician's Guide. NIH Publication no. 05-3769. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.
21. O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, et al. (2006). Controlled trial of naltrexone augmentation of nicotine replacement for smoking cessation. Archives of Internal Medicine 166, 667-674.
22. O'Malley SS, Garbutt JE, Gasfriend DR, Dong Q, Kranzler HR (2007). Efficacy of extended release naltrexone in alcohol dependent patients who are abstinent before treatment. Journalof Clinical Psychopharmacology 27, 507-512.
23. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry 49, 881-887.
24. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berlin) 160, 19-29.
25. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA (2006). The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Journal of Clinical Psychopharmacology 26, 610-625.
26. Radloff LS (1977). The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1, 385-401.
27. Reid MC, Fiellin DA, O'Connor PG (1999). Hazardous and harmful alcohol consumption in primary care. Archives of Internal Medicine 159, 1681-1689.
28. Srisurapanont M, Jarusuraisin N (2005). Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, Issue 1, Art. No.: CD001867. doi:10.1002/ 14651858.CD001867.pub2.
29. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda Jr. R, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcoholism: Clinical and Experimental Research 32, 58-66.
30. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49, 876-880.
31. Wilk AI, Jensen NM, Havighurst TC (1997). Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. Journal of General Internal Medicine 12, 274-283.